Research view
Switch to patient viewAlzheimer disease: trials that stopped early
Trials on Alzheimer disease that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
86 stopped trials give a reason in the registry, latest registry update first.
Terminated
Event-Related Potential (ERP) Components in Clinical Diagnosis
Reason given in the registry “The sponsor stopped funding the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Dec 2025.
- Ended
- May 2025
- Run by
- Boston University
- Registry record
- NCT05673759
Withdrawn
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
Reason given in the registry “sponsor decision to cancel project before enrollment.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Dec 2025.
- Run by
- C2N Diagnostics
- Registry record
- NCT06856681
Terminated
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
Reason given in the registry “It has been made the strategic decision to terminate the study. This decision to terminate the study early is not being made for safety reasons.”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2025.
- Ended
- Aug 2024
- Phase
- Phase 2
- Run by
- Vivoryon Therapeutics N.V.
- Registry record
- NCT03919162
Terminated
A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease
Reason given in the registry “Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Dec 2025.
- Ended
- Jun 2024
- Phase
- Phase 2
- Run by
- reMYND
- Registry record
- NCT05478031
Terminated
Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease
Reason given in the registry “Unexpected closure of study components -- the digital intervention (CBT-I) was no longer accessible, and alternatives were not feasible.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Nov 2025.
- Ended
- Jan 2024
- Run by
- University of California, San Francisco
- Registry record
- NCT03256539
Suspended
Development of Novel Measures for Alzheimer's Disease Prevention Trials
Reason given in the registry “The NYSPI site is currently paused and has been paused since an institutional pause on human subjects research began in June 2023. The U.S. Department of HHS Office of Human Research Protections (OHRP) issued a pause on human subjects research.”
Quoted unchanged from ClinicalTrials.gov; record updated 31 Oct 2025.
- Ended
- Aug 2026
- Run by
- New York State Psychiatric Institute
- Registry record
- NCT03900273
Terminated
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
Reason given in the registry “Terminated by Sponsor”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.
- Ended
- Mar 2024
- Phase
- Phase 2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04795466
Terminated
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Reason given in the registry “The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2025.
- Ended
- Sept 2024
- Phase
- Phase 3
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Registry record
- NCT02446132
Terminated
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Sept 2025.
- Ended
- Dec 2024
- Phase
- Phase 3
- Run by
- Cassava Sciences, Inc.
- Registry record
- NCT05026177
Terminated
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
Reason given in the registry “Sponsor Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Aug 2025.
- Ended
- Dec 2024
- Phase
- Phase 2
- Run by
- Cassava Sciences, Inc.
- Registry record
- NCT05352763
Terminated
Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease
Reason given in the registry “A temperature excursion occurred at the drug supplier's storage facility, which led to the loss of a significant portion of the IMP stock. Consequently, there is not enough IMP available to support continued recruitment”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2025.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Alzeca Biosciences, Inc.
- Registry record
- NCT05453539
Withdrawn
SNIFF - 3-Week Aptar CPS Device
Reason given in the registry “protocol being rewritten and submitted as new study”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Jul 2025.
- Phase
- Phase 2
- Run by
- Wake Forest University Health Sciences
- Registry record
- NCT05006599
Terminated
Study of ASN51 in Adults With Early Alzheimer's Disease
Reason given in the registry “Strategic decision”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jun 2025.
- Ended
- Nov 2024
- Phase
- Phase 2
- Run by
- Asceneuron S.A.
- Registry record
- NCT06677203
Terminated
Yizhi Baduanjin for Patients With Cognitive Impairment
Reason given in the registry “Only 1 subject has been recruited.”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Jun 2025.
- Ended
- Apr 2025
- Run by
- The University of Hong Kong
- Registry record
- NCT06453941
Withdrawn
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
Reason given in the registry “Company focus shifted”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Jun 2025.
- Run by
- ProgenaBiome
- Registry record
- NCT04100889
Terminated
Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study
Reason given in the registry “Loss of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Jun 2025.
- Ended
- May 2025
- Run by
- University of Colorado, Denver
- Registry record
- NCT02612376
Withdrawn
Clinical Trial of AGB101 for Mild Cognitive Impairment
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.
- Phase
- Phase 2
- Run by
- AgeneBio
- Registry record
- NCT05986721
Terminated
Ultrasonic Neuromodulation for Treatment of Cognitive Impairment
Reason given in the registry “IRB administrative closure”
Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.
- Ended
- Aug 2024
- Phase
- Phase 1/2
- Run by
- University of Utah
- Registry record
- NCT06135051
Terminated
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Reason given in the registry “sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.
- Ended
- Jan 2025
- Phase
- Phase 3
- Run by
- Cassava Sciences, Inc.
- Registry record
- NCT05575076
Terminated
TMS as a Treatment for Apathy in Alzheimer's Disease
Reason given in the registry “Unable to fulfill recruitment goals”
Quoted unchanged from ClinicalTrials.gov; record updated 15 May 2025.
- Ended
- Oct 2024
- Run by
- Massachusetts General Hospital
- Registry record
- NCT05389644
Terminated
Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
Reason given in the registry “Lack of recruitment.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 May 2025.
- Ended
- Feb 2025
- Phase
- Phase 2
- Run by
- Sunnybrook Health Sciences Centre
- Registry record
- NCT02085265
Withdrawn
Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease
Reason given in the registry “withdrawn by the PI”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Apr 2025.
- Ended
- Apr 2026
- Phase
- Phase 4
- Run by
- Wake Forest University Health Sciences
- Registry record
- NCT06169826
Terminated
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Reason given in the registry “Sponsor's Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2025.
- Ended
- Aug 2024
- Phase
- Phase 3
- Run by
- Biogen
- Registry record
- NCT05310071
Terminated
ScentAware and OCT in MCI vs HC
Reason given in the registry “slow enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2025.
- Ended
- Jun 2024
- Run by
- University of Wisconsin, Madison
- Registry record
- NCT06377241
Withdrawn
Effect of Neuronavigated Theta-Burst Transcranial Magnetic Stimulation (TBS) for Early Alzheimer's Disease
Reason given in the registry “The study was terminated due to funding constraints and resource limitations that made further recruitment and continuation unfeasible.”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Apr 2025.
- Ended
- Mar 2025
- Run by
- Anhui Medical University
- Registry record
- NCT06524817
Terminated
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
Reason given in the registry “ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score.”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Apr 2025.
- Ended
- Oct 2024
- Phase
- Phase 2/3
- Run by
- LeonaBio
- Registry record
- NCT04886063
Terminated
An Innovative Platform for Objective Monitoring of Instrumental Activities of Daily Living
Reason given in the registry “The PI has moved to another institution”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Mar 2025.
- Ended
- Dec 2024
- Run by
- Bijan Najafi, PhD
- Registry record
- NCT05703490
Terminated
LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)
Reason given in the registry “Unable to recruit”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Mar 2025.
- Ended
- Apr 2024
- Phase
- Phase 3
- Run by
- LuMind IDSC Foundation
- Registry record
- NCT06860373
Terminated
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Reason given in the registry “Sponsor's Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Feb 2025.
- Ended
- Jul 2024
- Phase
- Phase 3
- Run by
- Biogen
- Registry record
- NCT04241068
Terminated
Home Test for Measuring Plasma P-tau217 in Alzheimer's Disease
Reason given in the registry “Lack of Funding”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Feb 2025.
- Ended
- Dec 2024
- Run by
- Insight Research Institute
- Registry record
- NCT06622135
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.